Aligos Therapeutics

Developer of therapies to treat hepatologic diseases and viral infections

placeSan Francisco, California, United States calendar_todayFounded 2018 groups70 employees language aligos.com

Registered entities

Social engagement

Social engagement: 7.5K social following, 9 posts in the last 12 months — below the industry typical range.

Investor mix

9 investors on record; lead investors include Wellington.

Investor typeCountShare
Venture capital333%
Private equity222%
Bank & private debt111%
Other / undisclosed333%

Recent activity

3 Jun 2026
Event
EASL | The Home of Hepatology Congress 2026
27 May 2026
Event
EASL Congress 2026
14 May 2026
Event
33rd European Congress on Obesity
Coming soon